– IRELAND, Dublin – Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Mary Sheahan as a Non-Executive Director to the Board with immediate effect
Mary Blake Sheahan, aged 44, is a dedicated senior leader with over 20 years’ experience, at Executive Committee level of a multinational publicly listed biopharmaceutical company. Mary’s most recent role was as Senior Vice President of Global Integration and Country Manager for Ireland with Perrigo Company plc, a NYSE-listed, $13 billion market cap leading global healthcare supplier. In this role, she was responsible for the successful integration of a $4.5bn acquisition of a leading European OTC Healthcare Company with operations in 35 countries.
Prior to this, Mary was Executive Vice President and Group Head of HR, IT, Facilities & Portfolio Assessment Management at Elan Corporation plc prior to its merger with Perrigo in 2013. Mary is a qualified chartered accountant having trained with KPMG.
Tony Richardson, Chief Executive Officer of Venn said:”Mary will be a great addition to the Board in a time of great progress and change at Venn. She has a proven track record of setting direction, strategic decision-making and delivering results in complex and challenging situations, across a range of disciplines including finance, strategy and commercial functions. She will add considerable value to our team.
About Venn Life Sciences
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation – Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division – Innovenn – focused primarily on breakthrough development opportunities in Skin Science.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.